Edge Therapeutics, Inc. Contracts & Agreements

95 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Placement Agency Agreement dated February 26, 2025, between PDS Biotechnology Corporation and A.G.P./Alliance Global Partners
Edge Therapeutics, Inc.
Biotechnology
2025
Form of Pre-Funded Warrant
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
2025
Form of Common Warrant
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
2025
Form of Securities Purchase Agreement dated February 26, 2025, by and between PDS Biotechnology Corporation and the Purchasers
Purchase Agreements
Edge Therapeutics, Inc.
Biotechnology
2025
Amended and Restated At Market Issuance Sales Agreement dated August 13, 2024 by and between the Company, B. Riley Securities, Inc., and H.C. Wainwright & Co., LLC
Sales Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2024
Amendment to the Eighth Amended and Restated Certificate of Incorporation
Edge Therapeutics, Inc.
Biotechnology
2024
Executive Employment Agreement by and between Stephan F. Toutain and PDS Biotechnology Corporation, effective as of May 1, 2024
Edge Therapeutics, Inc.
Biotechnology
NJ
2024
Executive Employment Agreement by and between Lars Boesgaard and PDS Biotechnology Corporation, effective as of November 28, 2023
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2024
Executive Employment Agreement by and between Kirk V. Shephard, M.D. and PDS Biotechnology Corporation, effective as of January 22, 2024
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2024
PDS Biotechnology Corporation 2019 Inducement Plan, as amended
Edge Therapeutics, Inc.
Biotechnology
DE
2024
Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2023
License Agreement dated as of December 30, 2022 by and between Merck KGaA, Darmstadt, Germany and PDS Biotechnology Corporation
License Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2023
Share Transfer Agreement by and between PDS Biotechnology Corporation and Merck KGaA, Darmstadt, Germany
Share Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2023
Venture Loan and Security Agreement, dated August 24, 2022, by and among Horizon Technology Finance Corporation, as a lender and collateral agent, Powerscourt Investments XXV, LP,...
Loan Agreements
Edge Therapeutics, Inc.
Biotechnology
CT
2022
Form of Warrant issued under the Venture Loan and Security Agreement, dated August 24, 2022
Loan Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2022
Executive Employment Agreement by and between Spencer Brown and PDS Biotechnology Corporation, effective as of June 1, 2022
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2022
Amended and Restated Preclinical/Clinical Collaboration and License Agreement dated as of November 30, 2020 by and between PDS Biotechnology Corporation and Farmacore Biotechnology
Collaboration Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2022
First Amendment to Preclinical/Clinical Collaboration and License Agreement dated as of November 22, 2021 by and between PDS Biotechnology Corporation and Farmacore Biotechnology
Collaboration Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2022
PDS Biotechnology Corporation 2019 Inducement Plan, as amended
Edge Therapeutics, Inc.
Biotechnology
DE
2022
Patent License Agreement dated as of November 5, 2021, by and between PDS Biotechnology Corporation and the U.S. Department of Health and Human Services, as represented by the...
License Agreements
Edge Therapeutics, Inc.
Biotechnology
2022
Option Agreement with University of Georgia Research Foundation, Inc. effective as of October 25, 2021
Edge Therapeutics, Inc.
Biotechnology
GA
2022
PDS Biotechnology Corporation Change of Control Severance Plan effective as of March 14, 2022
Change of Control Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2022
Amended and Restated Executive Employment Agreement by and between Frank K. Bedu-Addo and PDS Biotechnology Corporation, effective as of March 14, 2022
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2022
Executive Employment Agreement by and between Gregory Conn, Ph.D. and PDS Biotechnology Corporation, effective as of March 14, 2022
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2022
Executive Employment Agreement by and between Matthew Hill and PDS Biotechnology Corporation, effective as of March 14, 2022
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2022
Executive Employment Agreement by and between Lauren V. Wood, M.D. and PDS Biotechnology Corporation, effective as of March 14, 2022
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2022
Executive Employment Agreement by and between PDS Biotechnology Corporation and Matthew Hill, dated as of October 4, 2021
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2021
Amendment to Employment Agreement by and between PDS Biotechnology Corporation and Gregory Conn, Ph.D., effective as of June 17, 2021
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
2021
Underwriting Agreement, dated June 15, 2021, by and among PDS Biotechnology Corporation and Cantor Fitzgerald & Co
Underwriting Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2021
Executive Employment Agreement by and between the Company and Seth L. Van Voorhees, Ph.D
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2020
Form of Employee Stock Option Agreement under the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2020
Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2020
PDS Biotechnology Corporation 2019 Inducement Plan, as amended
Edge Therapeutics, Inc.
Biotechnology
DE
2020
Underwriting Agreement dated August 11, 2020
Underwriting Agreements
Edge Therapeutics, Inc.
Biotechnology
2020
Consulting Agreement (Michael King)
Consulting Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2020
Sublease Agreement, effective as of March 5, 2020, by and between PDS Biotechnology Corporation and COWI North America, Inc
Lease Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2020
Description of Securities
Edge Therapeutics, Inc.
Biotechnology
2020
Form of Underwriting Agreement
Underwriting Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2020
Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement, dated as of October 28, 2019, by and between PDS Biotechnology Corporation and MSD International GmbH
Collaboration Agreements
Edge Therapeutics, Inc.
Biotechnology
2019
Offer Letter, dated February 1, 2019, by and between PDS Biotechnology Corporation and Lauren V. Wood, M.D
Edge Therapeutics, Inc.
Biotechnology
2019
Employment Agreement, effective June 1, 2019, by and between PDS Biotechnology Corporation and Gregory Conn
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2019
Common Stock Purchase Agreement, dated July 29, 2019 between PDS Biotechnology Corporation and Aspire Capital Fund, LLC
Stock Agreements
Edge Therapeutics, Inc.
Biotechnology
IL
2019
Registration Rights Agreement, dated July 29, 2019, between PDS Biotechnology Corporation and Aspire Capital Fund, LLC
Registration Rights Agreements
Edge Therapeutics, Inc.
Biotechnology
IL
2019
Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Inducement Plan
Stock Agreements
Edge Therapeutics, Inc.
Biotechnology
2019
PDS Biotechnology Corporation 2019 Inducement Plan
Edge Therapeutics, Inc.
Biotechnology
DE
2019
Letter Agreement, dated as of February 3, 2019, by and among Edge Therapeutics, Inc., PDS Biotechnology Corporation and Brian A. Leuthner
Edge Therapeutics, Inc.
Biotechnology
2019
Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of January 24, 2019, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc. and PDS...
Merger Agreements
Edge Therapeutics, Inc.
Biotechnology
2019
Employment Agreement, dated October 11, 2018, by and between PDS Biotechnology Corporation and Frank K. Bedu-Addo
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2018
Consulting Services Agreement, dated December 15, 2014, by and between PDS Biotechnology Corporation and Gregory Freitag
Consulting Agreements
Edge Therapeutics, Inc.
Biotechnology
2018
Consulting Services Agreement, dated December 15, 2014, by and between PDS Biotechnology Corporation and DeLyle Bloomquist
Consulting Agreements
Edge Therapeutics, Inc.
Biotechnology
2018
Offer Letter, dated September 21, 2018, by and between PDS Biotechnology Corporation and Lauren Wood, MD
Edge Therapeutics, Inc.
Biotechnology
2018
Consulting Services Agreement, dated March 26, 2015, by and between PDS Biotechnology Corporation and Gregory Conn
Consulting Agreements
Edge Therapeutics, Inc.
Biotechnology
2018
Agreement and Plan of Merger and Reorganization, dated November 23, 2018, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc. and PDS Biotechnology Corporation
Merger Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2018
Form of Support Agreement, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc., PDS Biotechnology Corporation and certain of PDS Biotechnology Corporations directors,...
Merger Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2018
Form of Support Agreement, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc., PDS Biotechnology Corporation and certain of Edge Therapeutics, Inc.s directors, officers...
Merger Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2018
Executive Employment Agreement by and between Andrew Saik and Edge entered into as of October 31, 2017
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2017
Manufacturing and Supply Agreement by and between the Company and Oakwood Laboratories LLC, dated as of June 30, 2017
Supply Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2017
Amended and Restated Master Formulation Development Agreement by and between the Company and Oakwood Laboratories LLC, dated as of June 30, 2017
Development Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2017
Form of Subscription Agreement dated April 19, 2017, between Edge Therapeutics, Inc. and certain investors
Subscription Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2017
Separation and General Release Agreement, by and between Edge Therapeutics, Inc. and Andrew J. Einhorn, dated March 13, 2017
Separation Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2017
Form of Employee Stock Option Agreement
Stock Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2017
Employment Agreement by and between Alyssa Wyant and the Company, dated as of February 21, 2017
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2017
Form of Executive Stock Option Agreement
Stock Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2017
Amended and Restated Loan and Security Agreement, dated as of August 1, 2016, by and between the Company and Hercules Capital, Inc
Loan Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2016
Executive Employment Agreement by and between Daniel Brennan and Edge Therapeutics, Inc. entered into as of October 17, 2016
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2016
Lease, dated February 18, 2016, between The Connell Company and Edge Therapeutics, Inc
Lease Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2016
Master Formulation Development Agreement by and between the Company and Oakwood Laboratories LLC, dated as of March 12, 2015
Development Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2016
Warrant to Purchase 18,000 Shares of Common Stock issued to Maxim Partners LLC, dated as of October 6, 2015
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2015
EXECUTIVEEMPLOYMENT AGREEMENT
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
EDGE THERAPEUTICS, INC. 2010 EQUITY INCENTIVE PLAN
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2015
CONFIDENTIAL MATERIAL OMITTED AND FILEDSEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. AMENDMENT NO. 1 TO THE LICENSE AGREEMENT
Exchange Agreements
Edge Therapeutics, Inc.
Biotechnology
2015
SECONDAMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
EDGE THERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN Adopted by the Board of DirectorsAugust 27, 2014 Approved by the Shareholders November 3, 2014
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2015
EDGE THERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2015
EDGE THERAPEUTICS, INC. Common Stock, par value $0.00033 pershare UNDERWRITING AGREEMENT
Underwriting Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2015
AMENDMENT TO THEedge therapeutics, inc. 2010 EQUITYINCENTIVE Plan
Edge Therapeutics, Inc.
Biotechnology
2015
AMENDEDAND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT
Loan Agreements
Edge Therapeutics, Inc.
Biotechnology
2015
EDGE THERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2015
FIRST AMENDMENT TO WARRANT NO. 1
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
2015
EDGE THERAPEUTICS, INC. WARRANT TO PURCHASE [______] SHARES OF COMMON STOCK
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
EDGE THERAPEUTICS, INC. Preferred Stock Warrant
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2015
WARRANT AGREEMENT To Purchase Shares of Preferred Stock of EDGE THERAPEUTICS, INC. Dated as of August28, 2014 (the Effective Date)
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2015
EDGE THERAPEUTICS, INC. Preferred Stock Warrant
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
NY
2015
INVESTORSRIGHTS AGREEMENT byand among EdgeTherapeutics, Inc., VenrockHealthcare Capital Partners II, L.P., and theother Investors named herein April6, 2015
Investor Rights Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2015
CONFIDENTIAL MATERIALOMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKSDENOTE SUCH OMISSIONS. LICENSE AGREEMENT
Exchange Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
EDGE THERAPEUTICS, INC. 2010 EQUITY INCENTIVE PLAN
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2015
EDGE THERAPEUTICS, INC. WARRANT TO PURCHASE 16,667 SHARES OF CAPITAL STOCK
Warrant Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
EDGE THERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN Adopted by the Board of DirectorsAugust 27, 2014 Approved by the Shareholders November 3, 2014
Bonus & Incentive Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2015
EDGE THERAPEUTICS,INC. SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
AMENDEDAND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
SECONDAMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
SECONDAMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Edge Therapeutics, Inc.
Biotechnology
NJ
2015
INDEMNIFICATION AGREEMENT
Indemnification Agreements
Edge Therapeutics, Inc.
Biotechnology
DE
2015
LOAN ANDSECURITY AGREEMENT
Loan Agreements
Edge Therapeutics, Inc.
Biotechnology
CA
2015